PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Evaluation of ruxolitinib, a Janus Kinase inhibitor, in multiple myeloma

Evaluation of ruxolitinib, a Janus Kinase inhibitor, in multiple myeloma
2024-02-07
(Press-News.org)

“[...] the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as well as other types of cancer.”

BUFFALO, NY- February 7, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

In this new paper, researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson from ONCOtherapeutics, Berenson Cancer Center, and Institute for Myeloma and Bone Cancer Research discussed multiple myeloma (MM) — the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. 

In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments. 

Recently, the Janus Kinase (JAK) family of tyrosine kinases, specifically JAK1 and JAK2, has been shown to have a role in the pathogenesis of MM. Preclinical studies have demonstrated a role for JAK signaling in direct and indirect growth of MM and downregulation of anti-tumor immune responses in these patients. Also, inhibition of JAK proteins enhances the anti-MM effects of other drugs used to treat MM. These findings have been confirmed in clinical studies which have further demonstrated the safety and efficacy of JAK inhibition as a means to overcome resistance to currently available anti-MM therapies. Additional studies will provide further support for this promising new therapeutic approach for treating patients with MM.

“The following sections of this article will be focused on studies of RUX [Ruxolitinib] in the preclinical [21–24] and clinical settings [18–20] focused on the treatment of relapsed/refractory (RR) MM.”

 

Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28547 

Correspondence to: James R. Berenson

Email: jberenson@berensoncancercenter.com 

Keywords: multiple myeloma, ruxolitinib, JAK/STAT, cytokine, clinical trial

Click here to sign up for free Altmetric alerts about this article.
 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

X, formerly Twitter Facebook YouTube Instagram LinkedIn Pinterest Reddit Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Oncotarget Journal Office

6666 East Quaker Street., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

###

END


[Attachments] See images for this press release:
Evaluation of ruxolitinib, a Janus Kinase inhibitor, in multiple myeloma

ELSE PRESS RELEASES FROM THIS DATE:

Blood thinners added to clot-busting medication did not improve stroke outcomes

2024-02-07
Research Highlights: Although giving blood thinners along with clot-busting medication may help in treating heart attacks, it did not improve 90-day outcomes in people with clot-caused strokes. Enrollment in a large clinical trial, which had been planned to include more than 1,200 patients with ischemic stroke (clot-caused stroke), was halted after an independent data and safety monitoring board found no indication of benefit among the first 500 patients. The data analysis for the 500 enrolled participants found giving blood thinners along with clot-busting medication did not increase the risk of bleeding into the brain. Embargoed ...

Reinforcing the diverse ways people access seafood can ensure healthy communities in the face of change

Reinforcing the diverse ways people access seafood can ensure healthy communities in the face of change
2024-02-07
(Santa Barbara, Calif.) — As climate change affects the oceans, coastal communities, particularly those at the front lines of ocean warming and sea level rise, are facing pressures that could threaten their access to aquatic foods. “Climate change and other economic shocks are impacting how people access seafood, and typically households that are most reliant on seafood, such as those in Pacific Island countries, are most at risk,” said Jacob Eurich, a research associate at UC Santa Barbara’s Marine Science Institute, and a fisheries scientist at the Environmental Defense Fund. Which is why, he added, it is necessary to increase food system resilience in the area, ...

Non-white victims of lethal violence and suicide in the US die significantly younger than their white counterparts

Non-white victims of lethal violence and suicide in the US die significantly younger than their white counterparts
2024-02-07
In the US, people of color who are killed by violence or die by suicide lose more potential years of life than white victims, according to a new study, which also explored factors that may contribute to these disparities. Gregory Zimmerman of Northeastern University in Boston, US, and colleagues present these findings in the open-access journal PLOS ONE on February 7, 2024. Mounting evidence suggests that, among victims of violence in the US, the average number of potential years of life lost—how much longer the victim would have lived if they survived—is greater for people of color than for white people. To deepen understanding, Zimmerman ...

Almost 1 in 5 Indian adults aged 60+ show signs of mild neurocognitive disorder, according to nationally representative data - more than previously recognized

Almost 1 in 5 Indian adults aged 60+ show signs of mild neurocognitive disorder, according to nationally representative data - more than previously recognized
2024-02-07
Almost 1 in 5 Indian adults aged 60+ show signs of mild neurocognitive disorder, according to nationally representative data - more than previously recognized ### Article URL:  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297220 Article Title: Prevalence of DSM-5 mild and major neurocognitive disorder in India: Results from the LASI-DAD Author Countries: USA, UK, India Funding: This work was supported by the National Institute on Aging (R01 AG051125 (JL), R01 AG030153 (JL), U01 AG064948 (JL), R01 AG070953 (ALG)). The funders had no role in study design, ...

More biodiverse nature landscapes may better buffer against stress - but only if you notice the difference, per experiment using videos of urban woodland

More biodiverse nature landscapes may better buffer against stress  - but only if you notice the difference, per experiment using videos of urban woodland
2024-02-07
More biodiverse nature landscapes may better buffer against stress  - but only if you notice the difference, per experiment using videos of urban woodland ### Article URL:  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297179 Article Title: Does increasing biodiversity in an urban woodland setting promote positive emotional responses in humans? A stress recovery experiment using 360-degree videos of an urban woodland Author Countries: UK Funding: SF received a PhD Studentship funding from the UKRI Economic and Social Research Council, ...

UK austerity politics correlated with increased frailty in the oldest adults

UK austerity politics correlated with increased frailty in the oldest adults
2024-02-07
The period of austerity politics from 2012 to 2018 was associated with steeper increases in frailty with age compared to pre-austerity between 2002 and 2010, according to a new study published February 7th in the open-access journal PLOS ONE by Carys Pugh of the University of Edinburgh, UK, and colleagues. Previous research has linked a stalling in life expectancy growth to austerity politics implemented in response to the 2008-2009 financial crisis. However, the mechanism through which public spending cuts are associated with decreased life expectancy ...

Psychology study unearths ways to bolster global climate awareness and climate action

2024-02-07
An international team of scientists has created a tool that can aid in increasing climate awareness and climate action globally by highlighting messaging themes shown to be effective through experimental research. The web-based tool, and the methods undergirding its creation, appears in the journal Science Advances. The tool stems from a study involving nearly 250 researchers that drew more than 59,000 participants from 63 countries, including Algeria, China, Denmark, Germany, Israel, Japan, New Zealand, Peru, and the United States.  “We ...

Scientists reveal why blueberries are blue

Scientists reveal why blueberries are blue
2024-02-07
Tiny external structures in the wax coating of blueberries give them their blue colour, researchers at the University of Bristol can reveal. This applies to lots of fruits that are the same colour including damsons, sloes and juniper berries. In the study, published today in Science Advances, researchers show why blueberries are blue despite the dark red colour of the pigments in the fruit skin. Their blue colour is instead provided by a layer of wax that surrounds the fruit which is made up of miniature structures that scatter blue and UV light. This gives blueberries their blue appearance to humans and blue-UV to birds. The chromatic blue-UV reflectance ...

McMaster and ALK researchers discover new cell that remembers allergies

2024-02-07
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abello A/S have made a groundbreaking discovery: a new cell that remembers allergies. The discovery gives scientists and researchers a new target in treating allergies and could lead to new therapeutics. The research, published in Science Translational Medicine on Feb. 7, 2024, coins the brand-new cell as a type-2 memory B cell (MBC2). “We’ve discovered a type of memory B cell that had unique characteristics and a unique gene ...

England’s oldest became frailer during austerity, study suggests

2024-02-07
The speed at which England’s oldest adults became frailer accelerated during the UK Government’s era of austerity politics, according to a new study.  Researchers say that the rate of frailty in people aged 85 and over in England increased 50 per cent faster per year between 2012 and 2018 compared with the preceding eight years.   The impact of frailty – a decline in a person’s mental and physical resilience to illness and injury – on the oldest in society must be considered should any new austerity measures be introduced, experts warn.    The study, led by researchers from the University of Edinburgh’s ...

LAST 30 PRESS RELEASES:

Face‑/edge‑shared 3D perovskitoid single crystals with suppressed ion migration for stable X‑ray detector

Multiple solutions help fly embryos overcome the fundamental problem of ‘tissue tectonic collision’

GLP-1 weight-loss drugs pose hidden risks for young women

Strategies for enhancing energy‑level matching in perovskite solar cells: An energy flow perspective

3D‑printed boron‑nitrogen doped carbon electrodes for sustainable wastewater treatment via MPECVD

Screening anionic groups within zwitterionic additives for eliminating hydrogen evolution and dendrites in aqueous zinc ion batteries

New tectonic geodynamics textbook bridges scientific disciplines

Tiny and powerful – metamaterial lenses for your phones and drones

Study used AI models to improve prediction of chronic kidney disease progression to end stage renal disease

Peanut shell biochar composite shows promise for removing antibiotic-resistant bacteria from aquaculture wastewater

Compact genetic light switches transform disease control

Sunglasses for plants, and sustainable agriculture

Nearly half of those with diabetes unaware they have the disease

Emergency department visits by uninsured children in Texas soar 45% after COVID-era federal funding ends

Bright children from poorer backgrounds twice as likely to receive hospital mental health treatment than affluent high-achievers

‘Artificial cartilage’ could improve arthritis treatment

Breathing device could have profound impact on survival for people with sleep apnoea and type 2 diabetes

Artificial intelligence assessment indicates stress levels in farmed Amazonian fish

Keith Cole receives grant to conduct integrated research on mobility, cognition and aging

Internationally recognized malaria researcher Stefan Kappe, Ph.D., appointed new director of the UM School of Medicine's Center for Vaccine Development and Global Health

Lung cancer genetics study launches open-source data platform to research community

Pre-conception radiation exposure from CT scans increases risk for miscarriage and birth defects

Boston University appoints Kenneth Lutchen to top research job

For video-on-demand platforms, release strategy matters: streaming episodes gradually boosts consumers’ searches, subscription rates

Sleep strengthens muscle and bone by boosting growth hormone levels. Here's how

Only 1 in 7 online health images show proper technique to accurately measure blood pressure

Children receiving biofeedback speech therapy improved faster than with traditional methods

Scientists discover why the flu is more deadly for older people

The salmon superfood you’ve never heard of

How does chemotherapy disrupt circadian rhythms?

[Press-News.org] Evaluation of ruxolitinib, a Janus Kinase inhibitor, in multiple myeloma